Browsing Tag
CDH6
3 posts
Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Antengene (SEHK: 6996.HK) presents ATG-125, ATG-106, and ATG-112 preclinical data at AACR 2026. Read what the results mean for its pipeline strategy.
Half of platinum-resistant ovarian cancer patients respond to Raludotatug deruxtecan in REJOICE-Ovarian01 trial
Find out how Raludotatug deruxtecan achieved a 50 % response rate in platinum-resistant ovarian cancer and what it means for future ADC therapies.
NextCure brings Simcere Zaiming’s SIM0505 to U.S. trials as ADC race accelerates in oncology
Find out how NextCure and Simcere Zaiming are expanding SIM0505’s Phase 1 program into the U.S. and redefining the future of ADC collaboration.